Literature DB >> 15486956

ANT2 expression under hypoxic conditions produces opposite cell-cycle behavior in 143B and HepG2 cancer cells.

Arnaud Chevrollier1, Dominique Loiseau, Fabien Gautier, Yves Malthièry, Georges Stepien.   

Abstract

Under hypoxic conditions, mitochondrial ATP production ceases, leaving cells entirely dependent on their glycolytic metabolism. The cytoplasmic and intramitochondrial ATP/ADP ratios, partly controlled by the adenine nucleotide translocator (ANT), are drastically modified. In dividing and growing cells that have a predominantly glycolytic metabolism, the ANT isoform 2, which has kinetic properties allowing ATP import into mitochondria, is over-expressed in comparison to control cells. We studied the cellular metabolic and proliferative response to hypoxia in two transformed human cell lines with different metabolic backgrounds: HepG2 and 143B, and in their rho(o) derivatives, i.e., cells with no mitochondrial DNA. Transformed 143B and rho(o) cells continued their proliferation whereas HepG2 cells, with a more differentiated phenotype, arrested their cell-cycle at the G(1)/S checkpoint. Hypoxia induced an increase in glycolytic activity, correlated to an induction of VEGF and hexokinase II (HK II) expression. Thus, according to their tumorigenicity, transformed cells may adopt one of two distinct behaviors to support hypoxic stress, i.e., proliferation or quiescence. Our study links the constitutive glycolytic activity and ANT2 expression levels of transformed cells with the loss of cell-cycle control after oxygen deprivation. ATP import by ANT2 allows cells to maintain their mitochondrial integrity while acquiring insensitivity to any alterations in the proteins involved in oxidative phosphorylation. This loss of cell dependence on oxidative metabolism is an important factor in the development of tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15486956     DOI: 10.1002/mc.20059

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  16 in total

1.  Transgenic overexpression of adenine nucleotide translocase 1 protects ischemic hearts against oxidative stress.

Authors:  Inga Klumpe; Konstantinos Savvatis; Dirk Westermann; Carsten Tschöpe; Ursula Rauch; Ulf Landmesser; Heinz-Peter Schultheiss; Andrea Dörner
Journal:  J Mol Med (Berl)       Date:  2016-04-15       Impact factor: 4.599

2.  Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination.

Authors:  Yun Choi; Yong H Jeon; Ji-Young Jang; June-Key Chung; Chul-Woo Kim
Journal:  Mol Ther       Date:  2010-11-09       Impact factor: 11.454

3.  Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.

Authors:  Ji-Young Jang; Yoon-Kyung Jeon; Yun Choi; Chul-Woo Kim
Journal:  Mol Cancer       Date:  2010-09-28       Impact factor: 27.401

4.  Deficiency in the mouse mitochondrial adenine nucleotide translocator isoform 2 gene is associated with cardiac noncompaction.

Authors:  Jason E Kokoszka; Katrina G Waymire; Adrian Flierl; Katelyn M Sweeney; Alessia Angelin; Grant R MacGregor; Douglas C Wallace
Journal:  Biochim Biophys Acta       Date:  2016-04-24

5.  Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells.

Authors:  Ji Young Jang; Min Kyoung Kim; Yoon Kyung Jeon; Yoon Ki Joung; Ki Dong Park; Chul Woo Kim
Journal:  Exp Mol Med       Date:  2012-04-30       Impact factor: 8.718

6.  Pathway-specific differences between tumor cell lines and normal and tumor tissue cells.

Authors:  Adam Ertel; Arun Verghese; Stephen W Byers; Michael Ochs; Aydin Tozeren
Journal:  Mol Cancer       Date:  2006-11-02       Impact factor: 27.401

7.  Defining the gene expression signature of rhabdomyosarcoma by meta-analysis.

Authors:  Chiara Romualdi; Cristiano De Pittà; Lucia Tombolan; Stefania Bortoluzzi; Francesca Sartori; Angelo Rosolen; Gerolamo Lanfranchi
Journal:  BMC Genomics       Date:  2006-11-07       Impact factor: 3.969

8.  Identification and characterization of renal cell carcinoma gene markers.

Authors:  Gul S Dalgin; Dustin T Holloway; Louis S Liou; Charles DeLisi
Journal:  Cancer Inform       Date:  2007-02-09

9.  ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma.

Authors:  Ji-Young Jang; Young-Sin Lee; Yoon-Kyung Jeon; Kyoungbun Lee; Ja-June Jang; Chul-Woo Kim
Journal:  Exp Mol Med       Date:  2013-01-10       Impact factor: 8.718

10.  Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo.

Authors:  Ji-Young Jang; Yun Choi; Yoon-Kyung Jeon; Chul-Woo Kim
Journal:  Breast Cancer Res       Date:  2008-02-12       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.